The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The Europe generic drug market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to continue its strong growth during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Generic drugs are pharmaceutical drugs with an equivalent therapeutic effect as their branded counterparts. These drugs are also identical to the innovator drug in terms of safety, strength, quality, dosage route of administration and intended usage. Unlike branded drugs, generic drugs are cost-efficient and they do not require hefty investments in marketing campaigns or clinical studies.
Governments of various countries in Europe, along with healthcare authorities, are presently concerned about inflating pharmaceutical prices. As a result, they are increasingly promoting the usage of generic drugs over their branded counterparts, which represents one of the significant factors propelling the growth of the market. Apart from this, low production costs of generic drugs are attracting manufacturers to make capital investments in the industry. Moreover, the rising utilization of 3D printing technology in the healthcare sector is resulting in the increasing launch of generic drugs with customized sizes, forms and textures. Furthermore, the high prevalence of chronic diseases in the region is propelling governing agencies to finance research and development (R&D) for launching new compounds and improving existing technologies.
IMARC Group provides an analysis of the key trends in each sub-segment of the Europe generic drug market, along with forecasts at the regional and country level from 2021-2026. Our report has categorized the market based on segment, therapy area, drug delivery and distribution channel.
Breakup by Segment:
Breakup by Therapy Area:
Breakup by Drug Delivery:
Breakup by Distribution Channel:
Breakup by Country:
The competitive landscape of the industry has also been examined along with the profiles of the key players.
|Base Year of the Analysis||2020|
|Segment Coverage||Segment, Therapy Area, Drug Delivery, Distribution Channel, Country|
|Countries Covered||Germany, France, United Kingdom, Italy, Spain, Others|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option|
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at